TARDBP and myeloid sarcoma: We utilized the clinical scoring method established for experimental autoimmune encephalomyelitis (EAE), a mouse model of MS, and found that Mobp-TDP43 cKO developed significant motor weakness within 90 days after Cre recombination (Figure 5E).